News from the 17th NIH Pediatric and Wildtype GIST Clinic

The NIH Pediatric and Wildtype GIST Clinic is a collaboration amongst researchers, specialists, patient advocates, patients and family members, with the goal of furthering the knowledge of SDH-deficient gastrointestinal stromal tumors (GIST) in order to develop more effective therapies.

By |2019-12-19T11:25:54-05:00October 29th, 2019|News, Newsletter, SDH-Deficient GIST|

17th NIH Pediatric and Wildtype GIST Clinic Held

The 17th Pediatric and Wildtype GIST Clinic was held at the National Institutes of Health in Bethesda, Maryland on September 25-27, 2019. The Clinic was a collaboration amongst researchers, specialists, patient advocates, patients, and family members, with the goal of furthering the knowledge of SDH-deficient Gastrointestinal Stromal (GIST) tumors in order to develop more effective therapies.

By |2019-10-07T15:49:22-04:00October 7th, 2019|News, Research, SDH-Deficient GIST|

LRG Webcast Series: Updates on the Temozolomide Trial

Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.

By |2020-07-09T17:44:13-04:00September 16th, 2019|Clinical Trials, SDH-Deficient GIST, Webcast|

New in SDH-Deficient Research – The Paraganglioma* Preclinical Project

The Pediatric SDH-Deficient GIST Consortium, which was launched at the Biden Cancer Summit, consists of an impressive team of researchers, clinicians, academics, and patient advocacy groups. A member of our consortium, Dr. Joshua D. [...]

By |2018-12-17T14:34:57-05:00December 17th, 2018|News, Newsletter, Research|

LRG Webcast: What is SDH, How Is It Related to Cancer, and What Can Be Done About It?

SDH is a protein that is based in the mitochondria. Its loss causes a major energy and metabolic crisis. Despite this, some types of cells can 'benefit' from the loss of SDH and continue to [...]

By |2018-12-12T11:18:57-05:00November 2nd, 2018|Webcast|
Go to Top